We transform preclinical drug development by utilizing patient-derived inducible pluripotent stem cells (iPSCs) and the latest advances in organoids—cell-derived 3D organotypic models. This approach allows us to study biological processes and drug responses longitudinally, enabling us to drive, monitor, and impact disease progression. Our initial focus is on heart disease.
First to offer patient-derived cardiac organoids for drug development.
Currently expanding into kidney organoids to broaden disease modeling capabilities.
We model the progression of heart disease, including structural changes and abnormal cell growth known as hypertrophy, using patient-derived iPSC-based 2D and 3D culture systems. These systems incorporate cardiomyocytes and interacting heart cells like fibroblasts, endothelial cells, and vascular smooth muscle cells. This comprehensive modeling allows for detailed examination of disease evolution in individual patients.
Incorporates multiple heart cell types for accurate tissue representation.
Enables ongoing observation of disease progression and therapeutic responses over time.
.png)
We offer a range of services designed to provide in-depth insights into disease mechanisms and therapeutic effects using patient-derived cells.
We can use iPSCs from patient samples, capturing individual genetic backgrounds for personalized disease modeling. This facilitates modeling the effects of specific gene mutations on disease development.
Our expertise in creating cardiac organoids allows for realistic modeling of heart tissue. These organoids enable the study of cardiac diseases and testing of therapeutic approaches that might work better in specific patients—a method validated in clinical studies of cardiomyopathy patients.
Building on our success with cardiac models, we are expanding into kidney organoid development. This will allow for advanced modeling of renal diseases, broadening the scope of our disease modeling capabilities.
Our modeling services empower researchers and pharmaceutical companies to gain unprecedented insights into disease mechanisms and therapeutic effects, ultimately accelerating the development of effective treatments.
Enables testing of therapeutic approaches tailored to individual genetic mutations.
Our approaches have been validated in clinical studies, enhancing confidence in translational potential.
Contact us today to discover how we can support your innovative work with personalized solutions.
We support preclinical drug discovery by creating opportunities to screen in human disease-relevant platforms before or after animal studies. By exploring the effects of drugs on iPSC-derived cells—such as cardiomyocytes—we employ strategies that could lead to "clinical trials in a dish," tailored down to the individual patient level.
Learn More
Empowering researchers to create and store iPSCs, unlocking the potential for groundbreaking treatments. Our innovations in stem cell science lay the foundation for future medical advancements.
Learn More